Nacubactam Enhances Meropenem Activity against Carbapenem-Resistant Klebsiella pneumoniae Producing KPC | Zendy

Melissa D. Barnes | Zendy; Magdalena A. Taracila | Zendy; Caryn E. Good | Zendy; Saralee Bajaksouzian | Zendy; Laura J. Rojas | Zendy; David van Duin | Zendy; Barry N. Kreiswirth | Zendy; Michael R. Jacobs | Zendy; Andreas Haldimann | Zendy; Krisztina M. PappWallace | Zendy; Robert A. Bonomo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Nacubactam Enhances Meropenem Activity against Carbapenem-Resistant Klebsiella pneumoniae Producing KPC

Author(s) -

Melissa D. Barnes,

Magdalena A. Taracila,

Caryn E. Good,

Saralee Bajaksouzian,

Laura J. Rojas,

David van Duin,

Barry N. Kreiswirth,

Michael R. Jacobs,

Andreas Haldimann,

Krisztina M. PappWallace,

Robert A. Bonomo

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00432-19

Subject(s) - klebsiella pneumoniae , meropenem , carbapenem resistant enterobacteriaceae , enterobacteriaceae , microbiology and biotechnology , antibiotics , carbapenem , klebsiella , biology , antibiotic resistance , escherichia coli , gene , biochemistry

Carbapenem-resistantEnterobacteriaceae (CRE) are resistant to most antibiotics, making CRE infections extremely difficult to treat with available agents.Klebsiella pneumoniae carbapenemases (KPC-2 and KPC-3) are predominant carbapenemases in CRE in the United States. Nacubactam is a bridged diazabicyclooctane (DBO) β-lactamase inhibitor that inactivates class A and C β-lactamases and exhibits intrinsic antibiotic and β-lactam “enhancer” activity againstEnterobacteriaceae .

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research